Boceprevir in Mexico: Experience in a Series of Cases

Autor:	Jorge Luis S, Alberto Chaparro-Sánchez, Jesús Gaytán-Martínez, Bulmaro Manjarrez-Tellez, oval-Ramirez, José Antonio Mata-Marín
Rok vydání:	2014
Předmět:	Pediatrics medicine.medical_specialty business.industry Ribavirin virus diseases Developing country Pharmacology Omics First generation chemistry.chemical_compound Peg interferon chemistry Boceprevir Mexico city medicine Hcv treatment business
Zdroj:	Journal of Gastrointestinal & Digestive System.
ISSN:	2161-069X
DOI:	10.4172/2161-069x.1000317
Popis:	There are many new drugs for HCV treatment. First generation protease inhibitors are about to be discontinued. However in developing countries the likelihood of access to these new drugs is vague. As in other poor countries, in Mexico we only have peg interferon and ribavirin for HCV treatment and the costs of the new therapies are hard to fill. This is a report of the outcome in 30 patients who received triple therapy adding Boceprevir to peg interferon and Ribavirin as part of an extended-access program. As described elsewhere Latinos have lower response rates. This is the largest series of cases in Mexico City, and we would like to share this experience with other developing countries.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b9cd4022aefd3082ab915f8806022f1f https://doi.org/10.4172/2161-069x.1000317 Zobrazit plný text záznamu